Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 21101-21110 Newer>

The Motley Fool February 27, 2007 Emil Lee	Is U.S. Concrete Still Solid? Should this one be in your portfolio mix? U.S. Concrete is a strong candidate for further due diligence -- and the answer seems to be a resounding yes.
The Motley Fool February 27, 2007 Billy Fisher	OSI Eyeing Growth in '07 Despite recent mixed results, the pharmaceutical has higher hopes for the year. Investors, take note.
The Motley Fool February 27, 2007 Seth Jayson	Quick Take: Stock Fraud Made Easy It's a brave new world. Or so it would seem for stock fraudsters engaged in sophisticated insider-trading schemes from overseas bases.
The Motley Fool February 27, 2007 Rich Smith	Foolish Forecast: Plug This Hole The fuel cell pioneer Plug Power will report its fourth-quarter and full-year 2006 earnings shortly. Investors, here is what you can expect to see.
The Motley Fool February 27, 2007 David Lee Smith	Confessions of a Wall Street Analyst Peer inside the strange, mixed-up world of securities analysis.
The Motley Fool February 27, 2007 Brian Lawler	FDA Keeps Novartis Waiting The pharmaceutical experiences a regulatory setback in the U.S. for one of its top drug candidates. Investors, take note.
The Motley Fool February 27, 2007 Brian Lawler	PDL Keeps Us Waiting PDL BioPharma announces its year-end financial results. Investors, take note.
The Motley Fool February 27, 2007 Brian Lawler	Three Strikes for Telik Investors, there's not much in the pipeline at this small biotech company.
The Motley Fool February 27, 2007 Brian Lawler	Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors.
The Motley Fool February 27, 2007 Brian Lawler	Mostly Good From BioMarin Drugmaker BioMarin updates investors on its drug pipeline and quarterly financial results.
<Older 21101-21110 Newer> Return to current articles.